These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28095679)

  • 21. Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases.
    Bose S; Cho J
    Arch Pharm Res; 2013 Sep; 36(9):1039-50. PubMed ID: 23771498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
    Magen I; Gozes I
    Neuropeptides; 2013 Dec; 47(6):489-95. PubMed ID: 24210139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitamin E and other endogenous antioxidants in the central nervous system.
    Vatassery GT
    Geriatrics; 1998 Sep; 53 Suppl 1():S25-7. PubMed ID: 9745632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repositioning Microtubule Stabilizing Drugs for Brain Disorders.
    Varidaki A; Hong Y; Coffey ET
    Front Cell Neurosci; 2018; 12():226. PubMed ID: 30135644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases.
    Krahn AI; Wells C; Drewry DH; Beitel LK; Durcan TM; Axtman AD
    ACS Chem Neurosci; 2020 Jul; 11(13):1871-1886. PubMed ID: 32464049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small molecule intervention in microtubule-associated human disease.
    Gerdes JM; Katsanis N
    Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R291-300. PubMed ID: 16244328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in microtubule-stabilizing agents.
    Cao YN; Zheng LL; Wang D; Liang XX; Gao F; Zhou XL
    Eur J Med Chem; 2018 Jan; 143():806-828. PubMed ID: 29223097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal delivery of biologics to the central nervous system.
    Lochhead JJ; Thorne RG
    Adv Drug Deliv Rev; 2012 May; 64(7):614-28. PubMed ID: 22119441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel therapeutics based on tau/microtubule dynamics: WO2008084483.
    Alonso Adel C; Corbo CP
    Expert Opin Ther Pat; 2009 Sep; 19(9):1335-8. PubMed ID: 19555159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
    Youdim MB; Buccafusco JJ
    Trends Pharmacol Sci; 2005 Jan; 26(1):27-35. PubMed ID: 15629202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-target compounds acting in the central nervous system designed from natural products.
    Chen X; Decker M
    Curr Med Chem; 2013; 20(13):1673-85. PubMed ID: 23410166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
    Field JJ; Kanakkanthara A; Miller JH
    Bioorg Med Chem; 2014 Sep; 22(18):5050-9. PubMed ID: 24650703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tau and axonopathy in neurodegenerative disorders.
    Higuchi M; Lee VM; Trojanowski JQ
    Neuromolecular Med; 2002; 2(2):131-50. PubMed ID: 12428808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets.
    Mammana S; Fagone P; Cavalli E; Basile MS; Petralia MC; Nicoletti F; Bramanti P; Mazzon E
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29533975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases.
    Mannila A; Rautio J; Lehtonen M; Järvinen T; Savolainen J
    Eur J Pharm Sci; 2005 Jan; 24(1):101-5. PubMed ID: 15626583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tools for the rational design of bivalent microtubule-targeting drugs.
    Marangon J; Christodoulou MS; Casagrande FV; Tiana G; Dalla Via L; Aliverti A; Passarella D; Cappelletti G; Ricagno S
    Biochem Biophys Res Commun; 2016 Oct; 479(1):48-53. PubMed ID: 27613098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy.
    Makani V; Zhang B; Han H; Yao Y; Lassalas P; Lou K; Paterson I; Lee VM; Trojanowski JQ; Ballatore C; Smith AB; Brunden KR
    Acta Neuropathol Commun; 2016 Sep; 4(1):106. PubMed ID: 27687527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.